LONG-TERM BEVACIZUMAB TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ARE RECEIVING FOLFOX4 AND FOLFIRI CHEMOTHERAPY

被引：0
|
作者：
Davidenko, Irina [1 ]
Kazantseva, Margarita [2 ]
Potemin, Sergey [2 ]
Elizbaryan, Karina [2 ]
Mamaeva, Elena [2 ]
Burdik, Oksana [2 ]
机构：
[1] Krasnodar City Oncol Ctr, Krasnodar, Russia
[2] Krasnodar Oncol Ctr, Krasnodar, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [11] Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
    Dehghani, Mehdi
    Hafezi, Nematollah
    Vojdani, Reza
    Ramzi, Mani
    Karimi, Mojtaba
    Nourani, Habib
    Zakerinia, Maryam
    Bahador, Zahra
    MIDDLE EAST JOURNAL OF CANCER, 2015, 6 (03) : 171 - 177
  • [12] Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Mizunuma, Nobuyuki
    Shinozaki, Eiji
    Ogura, Mariko
    Ozaka, Masato
    Takagi, Koichi
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [13] Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V.
    Ervin, T.
    Stella, P.
    Saltz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [14] PRELIMINARY EFFICACY OF BEVACIZUMAB WITH FIRST LINE CHEMOTHERAPY BY FOLFOX OR FOLFIRI FOR METASTATIC COLORECTAL CANCER (MCRC): AN ALGERIAN EXPERIENCE
    Bensalem, A.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 40 - 40
  • [15] Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens
    Huang, M. Y.
    Chen, M. J.
    Tsai, H. L.
    Kuo, C. H.
    Ma, C. J.
    Hou, M. F.
    Chuang, S. C.
    Lin, S. R.
    Wang, J. Y.
    GENETICS AND MOLECULAR RESEARCH, 2011, 10 (04): : 3002 - 3012
  • [16] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
    Bond, M. J. G.
    van Smeden, M.
    Degeling, K.
    Cremolini, C.
    Schmoll, H. J. E-V.
    Rossini, D.
    Ibach, S.
    Koopman, M.
    Punt, C. J. A.
    May, A. M.
    Kwakman, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
  • [17] Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4
    Dzunic, Miljana
    Andjelkovic-Apostolovic, Marija
    Vrbic, Svetislav
    Pejcic, Ivica
    Petkovic, Ivan
    Cvetanovic, Ana
    Dinic, Sasa
    JOURNAL OF BUON, 2020, 25 (01): : 212 - 219
  • [18] Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer
    Matsusaka, S.
    Mizunuma, N.
    Suenaga, M.
    Chin, K.
    Shinozaki, E.
    Watanabe, T.
    Kawazoe, Y.
    Kuboki, Y.
    Terui, Y.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [19] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Aparicio, Jorge
    Fernandez-Martos, Carlos
    Vicent, Jose M.
    Maestu, Inmaculada
    Llorca, Cristina
    Busquier, Isabel
    Campos, Jan M.
    Perez-Enguix, Daniel
    Balcells, Miquel
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
  • [20] Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors
    Lewandowski, T.
    Biernacka, R.
    Chmielowiec, M.
    Gryziak, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345